4//SEC Filing
Steele Robin Joan 4
Accession 0001209191-17-045984
CIK 0001401914other
Filed
Jul 20, 8:00 PM ET
Accepted
Jul 21, 5:03 PM ET
Size
9.3 KB
Accession
0001209191-17-045984
Insider Transaction Report
Form 4
Steele Robin Joan
Director
Transactions
- Award
Common Stock
2017-07-19+246,171→ 246,171 total(indirect: By Trust) - Award
Option to Purchase Common Stock
2017-07-19+2,200→ 2,200 totalExercise: $6.56Exp: 2027-07-19→ Common Stock (2,200 underlying)
Footnotes (5)
- [F1]In exchange for the issuance of shares of common stock and options to purchase shares of common stock of Dare Bioscience, Inc. (the "Corporation"), the Corporation acquired all of the issued and outstanding shares of common stock of Dare Bioscience Operations, Inc. ("Dare Operations") pursuant to the terms of a Stock Purchase Agreement, dated March 19, 2017, by and between the Corporation, Dare Operations and certain equityholders of Dare Operations party thereto, as filed with the Securities and Exchange Commission on Form 8-K on March 20, 2017 (such exchanges and issuances, the "Transaction").
- [F2]The shares of common stock of the Corporation reported reflect the 10 for 1 reverse stock split effected by the Corporation on July 20, 2017. These shares of common stock of the Corporation were received in connection with the Transaction in exchange for 1,212,685 shares of Dare Operations. On the effective date of the Transaction, the closing price of the common stock of the Corporation, as reported on The Nasdaq Capital Market, was $6.56 per share (on a post-split basis). Each share of common stock of Dare Operations was cancelled and exchanged for the right to receive 0.2029969047 shares of common stock of the Corporation (on a post-split basis).
- [F3]The exercise price reported reflects the 10 for 1 reverse stock split effected by the Corporation on July 20, 2017.
- [F4]Ms. Steele was awarded options to purchase shares of the Corporation's common stock in connection with her service as a member of the Board of Directors (the "Director Options") pursuant to the Corporation's 2014 Stock Incentive Plan and the Non-Employee Director Compensation Policy.
- [F5]The Director Options will vest in equal annual installments over a three-year period measured from the date of grant, subject to Ms. Steele's continued service to the Corporation and will become exercisable in full upon a change of control of the Corporation.
Documents
Issuer
Dare Bioscience, Inc.
CIK 0001401914
Entity typeother
Related Parties
1- filerCIK 0001301008
Filing Metadata
- Form type
- 4
- Filed
- Jul 20, 8:00 PM ET
- Accepted
- Jul 21, 5:03 PM ET
- Size
- 9.3 KB